Stay updated on Atezolizumab in High-Risk Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab in High-Risk Bladder Cancer Clinical Trial page.

Latest updates to the Atezolizumab in High-Risk Bladder Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page shows an updated revision tag from v3.6.3 to v3.6.4, indicating a small platform update to the Record History view. The change does not appear to alter study information or navigation.SummaryDifference0.0%

- Check18 days agoChange DetectedReturned: 2026-07-10 is now shown and the QC status is Has Not Concluded. New sections have been added to the history view, including More Information, Adverse Events, Outcome Measures (Results), Baseline Characteristics, Participant Flow, Documents Section, Contacts/Locations, and an updated Study Status entry (2026-06-15, 63).SummaryDifference0.6%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page footer’s revision label was updated from v3.6.2 to v3.6.3, indicating a small site update. This metadata change does not alter study information or how users interact with the page.SummaryDifference0.0%

- Check39 days agoChange DetectedThe footer now displays Revision: v3.6.2, replacing the previous Revision: v3.6.0. This reflects a small version update shown on the page.SummaryDifference0.0%

- Check46 days agoChange DetectedResults Submitted has been added to the study history, replacing No Results Posted. This reflects that the trial's results have been submitted for the record and are awaiting posting.SummaryDifference0.0%

- Check54 days agoChange DetectedThe study history shows that enrollment has ended for this trial, and the record has been updated to a new revision (v3.6.0), replacing the previous version.SummaryDifference0.2%

Stay in the know with updates to Atezolizumab in High-Risk Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab in High-Risk Bladder Cancer Clinical Trial page.